Reig Jofre and Leanbio create the joint venture Syna Therapeutics

by Gemma Escarré,

The pharmaceutical company Reig Jofre strengthens its commitment to open innovation and the development of injectable and freeze-dried products with the creation of the joint venture Syna Therapeutics, for the development of biopharmaceutical products in the field of biosimilar products and innovative molecules.

The new alliance is 50% owned by  LeanBio, a biotechnology company founded by Dr. Andreu Soldevila in 2014, specialized in the development of biological products, and 50% by Reig Jofre, who will provide its extensive expertise in the formulation, stabilization and pharmaceutical development of biological and injectable products.

Syna Therapeutics will be headed by Dr. Andreu Soldevila as CEO and Gabriel Roig, as the president of the board of directors, will also count on Isabel Amat, member of the board of CataloniaBio & HealthTech and Rafael Montilla. The headquarters are located in the Barcelona Science Park (PCB).

More information

Photo: Andreu Soldevila, of LeanBio, with Gemma Lahuerta, Gabriel Roig and Isabel Amat, of Reig Jofre - © Syna Therapeutics


To comment, please login or create an account